Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-28T03:24:59.760Z Has data issue: false hasContentIssue false

Elevated Cerebrospinal Fluid Noradrenaline in Tardive Dyskinesia

Published online by Cambridge University Press:  29 January 2018

Dilip V. Jeste
Affiliation:
Unit on Movement Disorders, Adult Psychiatry Branch, Division of Special Mental Health Research, Intramural Research Program, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D.C. 20032, USA
Dinshaw R. Doongaji
Affiliation:
Department of Psychiatry, K.E.M. Hospital and G.S. Medical College, Bombay, India
Markku Linnoila
Affiliation:
DICBR, National Institute of Alcohol Abuse and Alcoholism, Bethesda, Maryland 20205, USA

Summary

Cerebrospinal fluid was collected from 28 psychiatric (mostly schizophrenic) inpatients from Bombay, India. These included eight patients with tardive dyskinesia, five with spontaneous dyskinesia and 15 without dyskinesia. The samples were flown to the National Institute of Mental Health, Washington, D.C., where they were analyzed “blind” for concentrations of noradrenaline and several monoamine metabolites. Patients with tardive dyskinesia had significantly higher noradrenaline concentrations in the CSF as compared with the other two groups. Spontaneous dyskinesia group had significantly lower concentrations of homovanillic acid in the CSF. Our results support the hypothesis of noradrenergic hyperactivity, rather than postsynaptic dopamine receptor supersensitivity, in tardive dyskinesia.

Type
Research Article
Copyright
Copyright © 1984 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bowers, M. B. Jr., Moore, D. & Tarsy, D. (1979) Tardive dyskinesia: a clinical test of the supersensitivity hypothesis. Psychopharmacology, 61, 137–41.CrossRefGoogle ScholarPubMed
Goldstein, D. S., Feuerstein, G., Izzo, J. L. Jr., et al (1981) Validity and reliability of high pressure liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sciences, 28, 467–75.CrossRefGoogle Scholar
Hornykiewicz, O. (1976) Neurohumoral interactions and basal ganglia function and dysfunction. In The Basal Ganglia (ed. Yahr, M. D.). New York: Raven Press.Google Scholar
Jeste, D. V. & Wyatt, R. J. (1982a) Understanding and Treating Tardive Dyskinesia. New York: Guilford Press.Google Scholar
Jeste, D. V. & Wyatt, R. J. (1982b) Therapeutic strategies against tardive dyskinesia: Two decades of experience. Archives of General Psychiatry, 39, 103–16.CrossRefGoogle ScholarPubMed
Jeste, D. V., Linnoila, M., Fordis, C. M., et al (1982) Enzyme studies in tardive dyskinesia. III. Noradrenergic hyperactivity in a subgroup of TD patients. Journal of Clinical Psychopharmacology, 2, 318–20.CrossRefGoogle Scholar
Messiha, F. S. (1980) Biochemical studies after chronic administration of neuroleptics to monkeys. In Tardive Dyskinesia: Research and Treatment (eds. F, W. E., Smith, R. C., Davis, J. M. et al). New York: SP Medical and Scientific Books. Pp. 1325.CrossRefGoogle Scholar
Miller, R. G. (1966) Simultaneous Statistical Inference. New York: McGraw-Hill. Pp. 165–72.Google Scholar
Nagao, T., Ohshimo, T., Mitsunoby, K., et al (1979) Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biological Psychiatry, 14, 509–23.Google ScholarPubMed
Perenyi, A., Arato, M., Bagdy, G., et al (1981) Long-acting neuroleptics and tardive dyskinesia. Is the high acitivity of serum dopamine-β-hydroxylase indicative of “individual sensitivity”? Abstracts of the III World Congress of Biological Psychiatry, Stockholm, June 28–July 3, 1981, Abstract No. F368.Google Scholar
Petrucelli, B., Bakris, G., Miller, T., et al (1982) A liquid chromatographic assay for 5-hydroxytryptophen, serotonin and 5-hydroxyindoleacetic acid in human body fluids. Acta Pharmacologica et Toxicologica, (In press).CrossRefGoogle Scholar
Post, R. M., Lake, C. R., Jimmerson, D. C., et al (1978) Cerebrospinal fluid norepinephrine in affective illness. American Journal of Psychiatry, 135, 907–12.Google ScholarPubMed
Sternberg, D. E., van Kammen, D. P., Lake, C. R., et al (1981) The effect of pimozide on CSF norepinephrine in schizophrenia. American Journal of Psychiatry, 138, 1045–51.Google ScholarPubMed
Ziegler, M. G., Lake, C. R., Wood, J. H., et al (1977) Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood-cerebro-spinal fluid barrier for norepinephrine. Journal of Neurochemistry, 28, 677–79.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.